Ocumension's OT-301 Meets Primary Endpoint in Denali Phase III Trial
CompanyDrug

Ocumension’s OT-301 Meets Primary Endpoint in Denali Phase III Trial

Zhejiang Medicine Receives NMPA Approval for Phase 1 Trial of XC2309 Injection
CompanyDrug

Zhejiang Medicine Receives NMPA Approval for Phase 1 Trial of XC2309 Injection

Shanghai Bao Pharma Files for Hong Kong IPO, Aiming to Boost Biologics Development
CompanyDeals

Shanghai Bao Pharma Files for Hong Kong IPO, Aiming to Boost Biologics Development

Zhongsheng Pharma's Onradivir Granted Drug Registration in Macau
CompanyDrug

Zhongsheng Pharma’s Onradivir Granted Drug Registration in Macau

Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners
CompanyDeals

Tianjin Lisheng Plans RMB 1 Billion Fund with Strategic Partners

Hengrui Pharmaceuticals Reports 15.88% Revenue Growth in 2025 Semi-Annual Results
Company

Hengrui Pharmaceuticals Reports 15.88% Revenue Growth in 2025 Semi-Annual Results

China's NMPA Resumes Import of Vasudha's Loratadine API After Rectifications
Policy / Regulatory

China’s NMPA Resumes Import of Vasudha’s Loratadine API After Rectifications

Jazz Pharmaceuticals Secures Global Rights to Saniona's Epilepsy Drug SAN2355
CompanyDeals

Jazz Pharmaceuticals Secures Global Rights to Saniona’s Epilepsy Drug SAN2355

Kite Pharma Acquires Interius BioTherapeutics for $350 Million to Boost CAR Therapy Platform
CompanyDeals

Kite Pharma Acquires Interius BioTherapeutics for $350 Million to Boost CAR Therapy Platform

Ionis Pharmaceuticals' DAWNZERA Approved by FDA for HAE Prevention
CompanyDrug

Ionis Pharmaceuticals’ DAWNZERA Approved by FDA for HAE Prevention

InnoCare Pharma's ICP-723 Joins China's SPARK Project for Pediatric Solid Tumors
CompanyDrug

InnoCare Pharma’s ICP-723 Joins China’s SPARK Project for Pediatric Solid Tumors

Lifetech Scientific's PDA Occluder Gains NMPA Innovative Device Review Status
CompanyMedical Device

Lifetech Scientific’s PDA Occluder Gains NMPA Innovative Device Review Status